Cargando…

Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing

Resistance to multiple antiretroviral drugs among people living with HIV (PLWH) can result in a high pill burden, causing toxicity and drug interactions. Thus, the goal is to simplify treatment regimens while maintaining effectiveness. However, former resistance analysis data may not be current or c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rauschning, Dominic, Ehren, Ira, Heger, Eva, Knops, Elena, Fätkenheuer, Gerd, Suárez, Isabelle, Lehmann, Clara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384096/ https://www.ncbi.nlm.nih.gov/pubmed/37515133 http://dx.doi.org/10.3390/v15071444

Ejemplares similares

Prevalence of HIV drug-resistance mutations in HIV-infected Mexican patients heavily experienced to antiretroviral therapy
por: Gaytán-Martínez, JE, et al.
Publicado: (2010)

2510. Systematic Literature Review of Multiclass Resistance in Heavily Treatment Experienced Persons with HIV
por: Mauskopf, Josephine, et al.
Publicado: (2019)

Longitudinal comparison of HIV-1 plasma viral load and cellular proviral load
por: Schweitzer, Finja, et al.
Publicado: (2014)

1283. Pretreatment HIV-1 Drug Resistance in Transmission Clusters of the Cologne-Bonn Region, Germany
por: Stecher, Melanie, et al.
Publicado: (2018)

HIV-1C proviral DNA for detection of drug resistance mutations
por: Huruy, Kahsay, et al.
Publicado: (2018)

2502. Impact of Pharmacist-Led Antiretroviral Therapy Simplification Initiative in Heavily Treatment-Experienced Patients on Virologic Control
por: Jimenez, Humberto R, et al.
Publicado: (2019)

Correction: HIV-1C proviral DNA for detection of drug resistance mutations
por: Huruy, Kahsay, et al.
Publicado: (2018)

HIV: how to manage heavily treatment-experienced patients
por: Spivack, Stephanie, et al.
Publicado: (2022)

1767. Structured Treatment Interruptions in HIV-Infected Patients Receiving Antiretroviral Therapy—Implications for Future HIV Cure Trials: A Systematic Review and Meta-analysis
por: Stecher, Melanie, et al.
Publicado: (2018)

Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia
por: Miti, Sam, et al.
Publicado: (2020)

108. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
por: Gandhi, Rajesh, et al.
Publicado: (2020)

Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid
por: Stella-Ascariz, Natalia, et al.
Publicado: (2016)

Feasibility of testing and detection of HIV-1 drug resistance in proviral DNA
por: Booth, Clare L, et al.
Publicado: (2014)

Understanding drug resistance patterns across different classes of antiretrovirals used in HIV-1-infected treatment-Naïve and experienced patients in Mumbai, India
por: Harjani, Raj Gurubuxrai, et al.
Publicado: (2022)

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens
por: De La Cruz, Justin, et al.
Publicado: (2019)

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results
por: Ogbuagu, Onyema, et al.
Publicado: (2022)

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results
por: Ogbuagu, Onyema, et al.
Publicado: (2023)

Molecular epidemiology of antiretroviral resistance in therapy-experienced HIV-1 patients in Cuba (2009)
por: Pérez, L, et al.
Publicado: (2010)

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1
por: Gartland, Margaret, et al.
Publicado: (2022)

CpG Methylation Profiles of HIV-1 Proviral DNA in Individuals on ART
por: Boltz, Valerie F., et al.
Publicado: (2021)

Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans
por: Musingwini, Tutsirai V., et al.
Publicado: (2017)

The Successful Application of a National Peer Advisory Committee for Physicians Who Provide Salvage Regimens to Heavily Antiretroviral-Experienced Patients in Mexican Human Immunodeficiency Virus Clinics
por: Calva, Juan J., et al.
Publicado: (2014)

CXCR3 Expression Pattern on CD4+ T Cells and IP-10 Levels with Regard to the HIV-1 Reservoir in the Gut-Associated Lymphatic Tissue
por: Augustin, Max, et al.
Publicado: (2022)

Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes
por: Hsu, Ricky K., et al.
Publicado: (2023)

Prevalence and incidence of hypertension in a heavily treatment-experienced cohort of people living with HIV in Uganda
por: Byonanebye, Dathan M., et al.
Publicado: (2023)

1280. Geospatial Spread of HIV in the Cologne-Bonn Region, Germany: From 2001 to 2016
por: Stecher, Melanie, et al.
Publicado: (2018)

SARS-CoV-2–neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma
por: Malin, Jakob J., et al.
Publicado: (2022)

The Time Response of Glass Resistive Plate Chambers to Heavily Ionizing Particles
por: Artamonov, A., et al.
Publicado: (2007)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients
por: Bossard, Claire, et al.
Publicado: (2021)

CRISPR based editing of SIV proviral DNA in ART treated non-human primates
por: Mancuso, Pietro, et al.
Publicado: (2020)

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d’Ivoire West Africa
por: Tchounga, Boris K., et al.
Publicado: (2020)

HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program
por: Derache, Anne, et al.
Publicado: (2015)

Emergence of HIV-1 drug resistance in antiretroviral therapy experienced perinatally infected children in South India
por: Neogi, Ujjwal, et al.
Publicado: (2012)

Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999–2008
por: Buchacz, Kate, et al.
Publicado: (2012)

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2012)

A study of antiretroviral resistance patterns in treatment experienced and naive human immunodeficiency virus infected-patients
por: Harjani, Raj, et al.
Publicado: (2016)

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
por: Ackerman, Peter, et al.
Publicado: (2021)

Fitness Cost of Antiretroviral Drug Resistance Mutations on the pol Gene during Analytical Antiretroviral Treatment Interruption among Individuals Experiencing Virological Failure
por: Hunter, James R., et al.
Publicado: (2021)

Absence of Resistance Mutations in the Integrase Coding Region among ART-Experienced Patients in the Republic of the Congo
por: Got, Ferdinand Emaniel Brel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_12v9cs4mqk3jpu17h3rbfdc9bc